[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339644-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339644-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","in-silico-exploration-of-anti-prostate-cancer-compounds-from-differential-expressed-genes","In silico exploration of anti-prostate cancer compounds from differential expressed genes","","Prostate cancer (PCa) is a complex, biologically diverse disease without curative treatment options. This study applies computational workflows to identify potential anti-PCa compounds from differentially expressed genes (DEGs), aiming to discover novel therapeutic indications or repurpose existing drugs. DEGs-to-drug prediction, pharmacokinetics prediction, target prediction, network analysis, and molecular docking were used. Results included 79 upregulated and 110 downregulated DEGs linked to drug candidates acting on multiple targets; docking highlighted specific binding interactions. Further validation requires preclinical and clinical studies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/in-silico-exploration-of-anti-prostate-cancer-compounds-from-differential-expressed-genes/339644/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/in-silico-exploration-of-anti-prostate-cancer-compounds-from-differential-expressed-genes/339644.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study?","Question",{"text":63,"@type":64},"To use computational methods to explore potential anti-prostate cancer compounds derived from differentially expressed genes, including drug repurposing or new therapeutic indications.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which computational methods are applied in the workflow?",{"text":68,"@type":64},"The study uses DEGs-to-drug prediction, pharmacokinetics prediction, target prediction, network analysis, and molecular docking.",{"name":70,"@type":61,"acceptedAnswer":71},"What kinds of results were identified for drug candidates?",{"text":72,"@type":64},"The analysis reported 79 upregulated and 110 downregulated DEGs and proposed drugs capable of reversing dysregulated states on several molecular targets, supported by docking binding interactions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339644,1791095973,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Ajiboye etal. BMC Urology (2024) 24:138 [https://doi.org/10.1186/s12894-024-01521-9](https://doi.org/10.1186/s12894-024-01521-9)  \nBMC Urology  \n RESEARCH Open Access  \nIn silico exploration of anti-prostate cancer   compounds from differential expressed genes  \nBasiru Olaitan Ajiboye1*, Toluwase Hezekiah Fatoki2, Olamilekan Ganiu Akinola1,  \nKazeem Olasunkanmi Ajeigbe3, Abraham Fisayo Bamisaye4, Eva‑María Domínguez‑Martín5,6, Patricia Rijo5 and Babatunji Emmanuel Oyinloye7,8  \nAbstract  \nProstate cancer (PCa) is a complex and biologically diverse disease with no curative treatment options at present.  \nThis study aims to utilize computational methods to explore potential anti‑PCa compounds based on differentially expressed genes (DEGs), with the goal of identifying novel therapeutic indications or repurposing existing drugs. The methods employed in this study include DEGs‑to‑drug prediction, pharmacokinetics prediction, target prediction, network analysis, and molecular docking. The findings revealed a total of 79 upregulated DEGs and 110 downregu‑ lated DEGs in PCa, which were used to identify drug compounds capable of reversing the dysregulated conditions (dexverapamil, emetine, parthenolide, dobutamine, terfenadine, pimozide, mefloquine, ellipticine, and trifluoperazine) at a threshold probability of 20% on several molecular targets, such as serotonin receptors 2a/2b/2c, HERG protein, adrenergic receptors alpha‑1a/2a, dopamine D3 receptor, inducible nitric oxide synthase (iNOS), epidermal growth factor receptor erbB1 (EGFR), tyrosine‑protein kinases, and C‑C chemokine receptor type 5 (CCR5) . Molecular docking analysis revealed that terfenadine binding to inducible nitric oxide synthase (‑7.833 kcal. mol−1) and pimozide binding to HERG (‑7.636 kcal. mol−1) . Overall, binding energy ΔGbind (Total) at 0 ns was lower than that of 100 ns for both the Terfenadine‑iNOS complex (‑101.707 to ‑103.302 kcal. mol−1) and Ellipticine‑TOPIIα complex (‑42.229 to ‑58.780 kcal. mol−1) . In conclusion, this study provides insight on molecular targets that could possibly contribute to the molecular mechanisms underlying PCa. Further preclinical and clinical studies are required to validate the therapeutic effective‑ ness of these identified drugs in PCa disease.  \nKeywords Prostate cancer, DEGs, ADMET, Molecular targets, Gene network, Molecular docking, Molecular dynamic simulation  \n*Correspondence: Basiru Olaitan Ajiboye [bash1428@yahoo.co.uk](bash1428@yahoo.co.uk)  \n1 Phytomedicine and Molecular Toxicology Research Laboratory, Department of Biochemistry, Federal University Oye‑Ekiti, Oye‑Ekiti, Ekiti State, Nigeria  \n2 Applied Bioinformatics Research Laboratory, Department of Biochemistry, Federal University Oye‑Ekiti, Oye‑Ekiti, Ekiti State, Nigeria  \n3 Department of Physiology, Faculty of Basic Medical Sciences, Federal University Oye‑Ekiti, Oye‑Ekiti, Ekiti State, Nigeria  \n4 Department of Biochemistry, Federal University Oye‑Ekiti, Oye‑Ekiti, Ekiti State, Nigeria  \n5 CBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Lusófona University, Campo Grande 376, Lisbon 1749‑024, Portugal  \n6 Facultad de Farmacia, Departamento de Ciencias Biomédicas (Área de Farmacología), Universidad de Alcalá de Henares, Nuevos Agentes Antitumorales, AcciónTóxica Sobre Células Leucémicas, Ctra.  \nMadrid‑Barcelona km. 33,600, Alcalá de Henares, Madrid 28805, España  \n7 Phytomedicine, Biochemical Toxicology and Biotechnology Research Laboratories, Department of Biochemistry, College of Sciences, Afe Babalola University, Ado‑Ekiti, Nigeria  \n8 Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa  \n© The Author(s) 2024, corrected publication 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or","cbCaig361ll3dBqm","https://ap.wps.com/l/cbCaig361ll3dBqm","pdf",3401246,21,"English","# Abstract\n# Introduction\n## Computational approach (DEGs-to-drug, ADMET, target and network prediction)\n## Differentially expressed genes and drug candidates\n## Molecular docking and binding energy results\n## Conclusion and future validation","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To use computational methods to explore potential anti-prostate cancer compounds derived from differentially expressed genes, including drug repurposing or new therapeutic indications.\"},{\"question\":\"Which computational methods are applied in the workflow?\",\"answer\":\"The study uses DEGs-to-drug prediction, pharmacokinetics prediction, target prediction, network analysis, and molecular docking.\"},{\"question\":\"What kinds of results were identified for drug candidates?\",\"answer\":\"The analysis reported 79 upregulated and 110 downregulated DEGs and proposed drugs capable of reversing dysregulated states on several molecular targets, supported by docking binding interactions.\"}]","In silico exploration of anti-prostate cancer compounds from differential expressed genes | PDF",1790031368,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ee1270baff919c5718c7a14cfd8dcb4.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f58ae3df1d96aba217cf20e2779229a8.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/547721583c930234c519ddf12fcc252c.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d64983379536ebdb157e1766b76593b.webp",980,1301]